Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
40
TXG Quote, Financials, Valuation and Earnings
Last price:
$14.69
Seasonality move
:
-7.11%
Day range:
$14.59 - $14.99
52-week range:
$12.95 - $57.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.79x
P/B ratio:
2.46x
Volume:
901.8K
Avg. volume:
2M
1-year change:
-74.07%
Market cap:
$1.8B
Revenue:
$618.7M
EPS (TTM):
-$1.53
Analysts' Opinion
-
Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $20.29, 10x Genomics has an estimated upside of 38.28% from its current price of $14.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 4.57% downside risk from its current price of $14.67.
Fair Value
-
According to the consensus of 14 analysts, 10x Genomics has 38.28% upside to fair value with a price target of $20.29 per share.
TXG vs. S&P 500
-
Over the past 5 trading days, 10x Genomics has underperformed the S&P 500 by -3.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
10x Genomics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
10x Genomics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter 10x Genomics reported revenues of $151.7M.
Earnings Growth
-
10x Genomics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter 10x Genomics reported earnings per share of -$0.30.
Enterprise value:
1.4B
EV / Invested capital:
1.91x
Price / LTM sales:
2.79x
EV / EBIT:
--
EV / Revenue:
2.19x
PEG ratio (5yr expected):
-0.31x
EV / Free cash flow:
55.01x
Price / Operating cash flow:
70.12x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$419.3M
Return On Assets:
-19.4%
Net Income Margin (TTM):
-28.99%
Return On Equity:
-24.99%
Return On Invested Capital:
-24.99%
Operating Margin:
-27.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $503.7M | $591M | $629.7M | $153.6M | $151.7M | |
| Gross Profit | $392.6M | $412.9M | $419.3M | $95.5M | $106.4M | |
| Operating Income | -$160.7M | -$191.8M | -$180.3M | -$53.4M | -$41.5M | |
| EBITDA | -$129.1M | -$178M | -$131.1M | -$80.3M | -$23.7M | |
| Diluted EPS | -$1.48 | -$1.91 | -$1.53 | -$0.79 | -$0.30 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $900.5M | $744.1M | $629.4M | $562.3M | $593.9M | |
| Total Assets | $1B | $990.6M | $996.2M | $948.5M | $937.8M | |
| Current Liabilities | $145.6M | $100.4M | $126.9M | $104.7M | $121.2M | |
| Total Liabilities | $217.5M | $190.4M | $220.4M | $203.3M | $215M | |
| Total Equity | $825.1M | $800.2M | $775.8M | $745.2M | $722.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.5M | -$27.2M | $39.2M | -$25.3M | $21.6M | |
| Cash From Investing | -$345.3M | $87.2M | $32.1M | $4.9M | -$3.6M | |
| Cash From Financing | $19.7M | $13.1M | $12M | $4.4M | $156K | |
| Free Cash Flow | -$161.1M | -$113M | $25M | -$40.7M | $17.8M | |
TXG
Sector
Market Cap
$1.8B
$46.1M
Price % of 52-Week High
25.39%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-74.07%
-30.52%
Beta (5-Year)
1.839
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$14.30
200-day SMA
Sell
Level
$22.17
Bollinger Bands (100)
Sell
Level
14.94 - 21.68
Chaikin Money Flow
Buy
Level
58.5M
20-day SMA
Sell
Level
$15.17
Relative Strength Index (RSI14)
Sell
Level
47.18
ADX Line
Buy
Level
19.93
Williams %R
Neutral
Level
-57.8652
50-day SMA
Sell
Level
$15.27
MACD (12, 26)
Sell
Level
-0.37
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-59.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.354)
Buy
CA Score
(Annual)
Level (-0.0806)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4937)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Stock Forecast FAQ
In the current month, TXG has received 6 Buy ratings 8 Hold ratings, and 0 Sell ratings. The TXG average analyst price target in the past 3 months is $20.29.
-
Where Will 10x Genomics Stock Be In 1 Year?
According to analysts, the consensus estimate is that 10x Genomics share price will rise to $20.29 per share over the next 12 months.
-
What Do Analysts Say About 10x Genomics?
Analysts are divided on their view about 10x Genomics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that 10x Genomics is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is 10x Genomics's Price Target?
The price target for 10x Genomics over the next 1-year time period is forecast to be $20.29 according to 14 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is TXG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for 10x Genomics is a Hold. 8 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of TXG?
You can purchase shares of 10x Genomics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase 10x Genomics shares.
-
What Is The 10x Genomics Share Price Today?
10x Genomics was last trading at $14.69 per share. This represents the most recent stock quote for 10x Genomics. Yesterday, 10x Genomics closed at $14.67 per share.
-
How To Buy 10x Genomics Stock Online?
In order to purchase 10x Genomics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
